Loading
Every dated change on the records linked to EGFR-mutated non-small-cell lung cancer, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
PFS HR 0.
PFS HR 0.
ORR 43.
A milestone in how this cancer is treated.
Amivantamab produced durable responses in EGFR exon 20 insertion non-small-cell lung cancer after platinum chemotherapy; accelerated approval in May 2021.
A milestone in how this cancer is treated.
OS HR 0.
PFS 16 vs 8 months (HR 0.
A milestone in how this cancer is treated.